オプションチェーンは、Mira Pharmaceuticalsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Mira Pharmaceuticalsの市場センチメントを評価します。.

Mira Pharmaceuticals (NASDAQ:MIRA) 株価情報, オプションチェーン

Mira Pharmaceuticals

Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals Inc

MIRAI Corp

MIRAIT One Corp

MIRAMAR RESOURCES LTD by MIRAMAR RESOURCES LTD

MIRATI THERAPEUTICS INC COM

MIRACLE ENTMT INC by Miracle Entertainment Inc.

Miracle Entertainment Inc

MIRAGE ENERGY CORP by Mirage Energy Corporation

Mirage Energy Corp

MIRAMAR HOTE & INVST CO by Miramar Hotel & Investment Co., Ltd.

Miramar Hotel & Investment Co Ltd

TAKARA LEBEN CO LTD by Takara Leben Co., Ltd.

Mirarth Holdings Inc

MIRASOL RESOURCES LTD by Mirasol Resources Ltd.

Mirasol Resources Ltd

Miratap Inc

MIRAVANT MEDICAL TECHS by Miravant Medical Technologies

Miravant Medical Technologies

News

General

AMZN

Amazon Web Services Joins ServiceNow's Workflow Data Network Ecosystem To Unlock Real-time Insights, Increase Ai-driven Actions, And Create Seamless Enterprise Data Unification

RBC Capital analyst Mike Dahl maintains Fortune Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBIN#NYSE">FBIN</a>) with a Sector Perform and lowers the price target from $70 to $59.

Price Target

Analyst Ratings

FBIN

RBC Capital Maintains Sector Perform on Fortune Brands, Lowers Price Target to $59

Goldman Sachs analyst Richard Law maintains Viridian Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRDN#NASDAQ">VRDN</a>) with a Buy and lowers the price target from $31 to $27.

VRDN

Goldman Sachs Maintains Buy on Viridian Therapeutics, Lowers Price Target to $27

Macro Economic Events

Market Summary

Economics

INDA

MRVL

Benzinga Market Summary: FOMC Decision At 2:00 p.m. ET, Marvell Postpones Investor Day Amid Uncertainty, Disney Surges On Strong Q2 Report, India-Pakistan Tensions On Watch

RBC Capital analyst Daniel Perlin maintains Flywire (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYW#NASDAQ">FLYW</a>) with a Outperform and lowers the price target from $20 to $17.

FLYW

RBC Capital Maintains Outperform on Flywire, Lowers Price Target to $17

Tesla Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)&nbsp;<a target="_blank" href="https://www.benzinga.com/topic/tesla-china" rel="noreferrer noopener">China-made electric vehicle</a> sales in April dropped 6% year-over-year, extending declines for a seventh month.
Deliveries of China-made Model 3 and Model Y vehicles totaled 58,459 units in April, down 25.8% from March, Reuters reported Wednesday, citing the China Passenger Car Association (CPCA).
Deliveries of China-made Model 3 and Model Y vehicles accounted for exports to markets, including sales in Europe and China.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45238222/teslas-future-hinges-on-china-fsd-analyst-says" rel="noreferrer noopener">Tesla&#8217;s Future Hinges On China FSD: Goldman Sachs</a>
Tesla&#8217;s sales&nbsp;plunged across Europe&nbsp;in April as brand sentiment and political backlash weighed on growth. CEO Elon Musk has acknowledged the challenges of running his business while working with the Department of Government Efficiency (DOGE).&nbsp;
Meanwhile, Tesla&#8217;s Chinese competitors have increased their market share. Tesla stock has lost 28% in stock value year-to-date.
Tesla ramped up efforts to sell into new markets such as&nbsp;India&nbsp;and&nbsp;Saudi Arabia to gain market share akin to its Chinese EV rivals.
Tesla also remains focused on commercializing the affordable version of Model Y in Shanghai in 2026.
Tesla&#8217;s <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/04/44607859/teslas-deliveries-slide-in-q1-amid-production-setbacks-political-backlash" rel="noreferrer noopener">first-quarter deliveries</a> dropped to 336,681 vehicles, down from 386,810 vehicles a year ago, amid production disruptions and weakening global demand. The electric vehicle company produced 362,615 vehicles, down from&nbsp;433,371 a year ago.
Tesla&#8217;s <a target="_blank" href="https://www.benzinga.com/government/regulations/25/03/44330619/tesla-bets-on-low-cost-evs-in-china-after-february-sales-hit-two-year-low" rel="noreferrer noopener">market share in</a> China&#8217;s battery-only EV market fell to 10.4% in 2024 from 11.7% in 2023 as it battled intense competition from Xiaomi (OTC:<a class="ticker" href="https://www.benzinga.com/stock/XIACF#OTC">XIACF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/XIACY#OTC">XIACY</a>). BYD (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDF#OTC">BYDDF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>) and Xiaomi have launched dozens of models to compete with Tesla.
Price Action: TSLA stock is down 0.31% at $274.50 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45221976/ferrari-beats-q1-holds-2025-outlook-but-warns-tariffs-could-squeeze-profit-margins" target="_blank" rel="noreferrer noopener">Ferrari Beats Q1, Holds 2025 Outlook But Warns Tariffs Could Squeeze Profit Margins</a></li>
</ul>
Image via Shutterstock

Asia

Government

Regulations

Emerging Markets

Tech

Media

BYDDF

BYDDY

TSLA

XIACF

XIACY

What Is Going On With Tesla Stock On Wednesday?

RBC Capital analyst Daniel Perlin maintains Fidelity National Info (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>) with a Outperform and lowers the price target from $95 to $93.

RBC Capital Maintains Outperform on Fidelity National Info, Lowers Price Target to $93

InfuSystems Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INFU#AMEX">INFU</a>) will release its quarterly earnings report on Thursday, 2025-05-08. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate InfuSystems Holdings to report an earnings per share (EPS) of $-0.03.
Investors in InfuSystems Holdings are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Overview of Past Earnings</h3>
In the previous earnings release, the company missed EPS by $0.02, leading to a 3.71% drop in the share price the following trading session.
Here's a look at InfuSystems Holdings's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.06</td>
<td>0.06</td>
<td>0.04</td>
<td>0.02</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.04</td>
<td>0.08</td>
<td>0.03</td>
<td>-0.05</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.0%</td>
<td>6.0%</td>
<td>0.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746637750_0.png" alt="eps graph" />
<h3>InfuSystems Holdings Share Price Analysis</h3>
Shares of InfuSystems Holdings were trading at $4.7 as of May 06. Over the last 52-week period, shares are down 36.37%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/INFU/earnings">To track all earnings releases for InfuSystems Holdings visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

INFU

InfuSystems Holdings's Earnings Outlook

Goldman Sachs analyst Ryan Nash maintains UWM Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UWMC#NYSE">UWMC</a>) with a Neutral and lowers the price target from $7 to $6.

UWMC

Goldman Sachs Maintains Neutral on UWM Holdings, Lowers Price Target to $6

RBC Capital analyst Kenneth Lee maintains Federated Hermes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHI#NYSE">FHI</a>) with a Sector Perform and raises the price target from $37 to $43.

RBC Capital Maintains Sector Perform on Federated Hermes, Raises Price Target to $43

Sarepta Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) reported on Tuesday that the first-quarter 2025 loss of&nbsp;$3.42 per share was missing the analyst consensus estimate of&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">losses of 95 cents</a>.
Quarterly revenue came in at $744.86 million,&nbsp;beating the consensus <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45235113/sarepta-therapeutics-announces-first-quarter-2025-financial-results-and-recent-corporate-developme" rel="noreferrer noopener">estimate of&nbsp;$683.36 million</a>.
According to Sarepta CEO Doug Ingram, the company also <a href="https://www.benzinga.com/general/biotech/25/05/45254051/vinay-prasads-appointment-to-fdas-cber-triggers-questions-over-future-of-cell-and-gene-therapy-re" target="_blank" rel="noreferrer noopener">faced headwinds in the quarter</a>. 
&#8220;While we are taking a variety of actions to address and resolve these challenges, we have adjusted our guidance for 2025 to $2.3 billion to $2.6 billion,&#8221; Ingram said. &#8220;The broader biotech market has also faced significant pressure in the first quarter of 2025. Fortunately, as an organization with four life-changing therapies, significant revenue, and a deep pipeline, Sarepta is well-positioned to navigate these chaotic times.&#8221;
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44634689/sareptaroche-suspend-elevidys-gene-therapy-trials-in-europe-after-patient-death" rel="noreferrer noopener">Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death</a>
Guidance: Sarepta revised its 2025 total net product revenues guidance to $2.3-$2.6 billion <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b42954480/sarepta-therapeutics-reports-preliminary-fourth-quarter-and-full-year-2024-net-product-revenue" rel="noreferrer noopener">from $2.9-$3.1 billion</a>.
William Blair writes that the revised guidance primarily relates to delayed Elevidys turnaround times.
The time from starting treatment paperwork to actual infusion takes about 1 to 1.5 months longer than expected. This delay is mostly due to stricter screening steps added to protect patients in the larger treatment group, analyst Sami Corwin says. Although the company is trying to speed things up and reduce delays, it expects these early-year trends to continue throughout the rest of the year.
&#8220;We view the miss in total net product and Elevidys revenue as unfortunate and disappointing given the macroeconomic overhangs that have already caused the stock to come under pressure,&#8221; William Blair writes.
The analyst adds that management believes the impact on Elevidys's revenue will be temporary, and expects demand to pick up in the second half of the year, starting in the summer.
<ul>
<li>William Blair maintains <a href="https://www.benzinga.com/quote/SRPT/analyst-ratings" target="_blank" rel="noreferrer noopener">the Outperform rating</a>.</li>
<li>Guggenheim maintains Sarepta with a Buy, lowering the price target from $112 to $98.</li>
<li>Piper Sandler keeps the Overweight rating for Sarepta, lowering the price target from $110 to $70.</li>
<li>Oppenheimer maintains Sarepta with an Outperform, lowering the price target from $184 to $123.</li>
<li>Cantor Fitzgerald reaffirms the company&#8217;s Overweight rating and lowers the price target from $163 to $81.</li>
<li>HC Wainwright maintains Sarepta with a Neutral, lowering the price target from $75 to $40.</li>
<li>Morgan Stanley maintains Sarepta with an Overweight, lowering the price target from $182 to $113.</li>
<li>Needham maintains Sarepta with a Buy and lowers the price target from $183 to $125.</li>
</ul>
Price Action: Sarepta Therapeutics stock is down 19.4% at $37.67 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45258853/geo-missed-q1-targets-on-rising-costs-and-debt-guides-q2-below-street-estimates" target="_blank" rel="noreferrer noopener">GEO Missed Q1 Targets On Rising Costs And Debt, Guides Q2 Below Street Estimates</a></li>
</ul>
Image: Shutterstock

Analyst Color

Biotech

Guidance

Health Care

Movers

Trading Ideas

SRPT

Sarepta Therapeutics Stock Sinks On Gloomy Forecast, Analysts Expect Demand To Pick Up

<h3>Gainers</h3>
<ul>
<li>NWTN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) stock rose 26.2% to $0.64 during Wednesday's regular session. The market value of their outstanding shares is at $184.1 million. </li>
<li>Purple Innovation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPL#NASDAQ">PRPL</a>) shares moved upwards by 19.98% to $0.89. The market value of their outstanding shares is at $96.6 million. The company's, Q1 earnings came out yesterday. </li>
<li>Mingteng International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEN#NASDAQ">MTEN</a>) shares rose 17.67% to $14.42. The company's market cap stands at $98.5 million. </li>
<li>Denny's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DENN#NASDAQ">DENN</a>) stock increased by 16.11% to $4.54. The company's market cap stands at $232.6 million. As per the press release, Q1 earnings came out 2 days ago. </li>
<li>Steven Madden (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOO#NASDAQ">SHOO</a>) shares moved upwards by 15.79% to $23.31. The company's market cap stands at $1.6 billion. As per the press release, Q1 earnings came out today. </li>
<li>ECD Automotive Design (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECDA#NASDAQ">ECDA</a>) shares increased by 15.69% to $0.37. The company's market cap stands at $12.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>WW International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WW#NASDAQ">WW</a>) stock decreased by 36.0% to $0.51 during Wednesday's regular session. The market value of their outstanding shares is at $40.5 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Ruanyun Edai Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYET#NASDAQ">RYET</a>) stock fell 24.97% to $5.41. The market value of their outstanding shares is at $182.5 million. </li>
<li>QVC Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QVCGA#NASDAQ">QVCGA</a>) shares decreased by 21.38% to $0.19. The company's market cap stands at $76.1 million. The company's, Q1 earnings came out today. </li>
<li>Jeffs Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFBR#NASDAQ">JFBR</a>) stock fell 20.19% to $0.87. The company's market cap stands at $1.6 million. </li>
<li>Lixiang Education Hldg (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXEH#NASDAQ">LXEH</a>) shares declined by 19.92% to $2.79. The company's market cap stands at $3.2 million. </li>
<li>Greenlane Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares fell 19.24% to $0.01. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DENN

ECDA

GNLN

JFBR

LXEH

MTEN

NWTN

PRPL

QVCGA

RYET

SHOO

12 Consumer Discretionary Stocks Moving In Wednesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares increased by 25.4% to $189.28 during Wednesday's regular session. The company's market cap stands at $2.4 billion. </li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) stock increased by 23.37% to $0.4. The company's market cap stands at $4.3 million. </li>
<li>Elanco Animal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) stock moved upwards by 20.66% to $11.47. The market value of their outstanding shares is at $5.6 billion. The company's, Q1 earnings came out today. </li>
<li>Beta Bionics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBNX#NASDAQ">BBNX</a>) shares moved upwards by 19.47% to $13.56. The market value of their outstanding shares is at $587.8 million. The company's, Q1 earnings came out yesterday. </li>
<li>Phio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) stock rose 18.02% to $2.03. The company's market cap stands at $9.6 million. </li>
<li>Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) stock moved upwards by 17.77% to $69.94. The market value of their outstanding shares is at $8.6 billion. The company's, Q1 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) stock declined by 44.6% to $0.09 during Wednesday's regular session. The market value of their outstanding shares is at $2.4 million. </li>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) stock fell 41.43% to $0.8. The company's market cap stands at $2.2 million. </li>
<li>Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) stock decreased by 36.46% to $4.62. The company's market cap stands at $425.8 million. The company's, Q1 earnings came out yesterday. </li>
<li>Pasithea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>) shares decreased by 29.61% to $1.07. The company's market cap stands at $2.8 million. </li>
<li>AquaBounty Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQB#NASDAQ">AQB</a>) shares decreased by 26.03% to $0.7. The market value of their outstanding shares is at $2.6 million. </li>
<li>Agilon Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) stock decreased by 24.03% to $3.39. The market value of their outstanding shares is at $1.3 billion. As per the news, the Q1 earnings report came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BBNX

ELAN

HALO

HEPA

KTTA

MYGN

PHIO

TOVX

12 Health Care Stocks Moving In Wednesday's Intraday Session

Goldman Sachs analyst George Tong maintains UL Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ULS#NYSE">ULS</a>) with a Neutral and raises the price target from $57 to $63.

Goldman Sachs Maintains Neutral on UL Solutions, Raises Price Target to $63

<h3>Gainers</h3>
<ul>
<li>Hyperscale Data (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GPUS#AMEX">GPUS</a>) shares rose 63.0% to $7.66 during Wednesday's regular session. The market value of their outstanding shares is at $11.7 million. </li>
<li>OneConstruction Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONEG#NASDAQ">ONEG</a>) stock rose 55.44% to $3.14. The company's market cap stands at $40.8 million. </li>
<li>Concorde Intl Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIGL#NASDAQ">CIGL</a>) stock rose 46.59% to $6.45. The market value of their outstanding shares is at $142.7 million. </li>
<li>GrafTech International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAF#NYSE">EAF</a>) shares rose 34.14% to $0.79. The company's market cap stands at $204.3 million. </li>
<li>Eos Energy Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) stock increased by 30.45% to $6.58. The company's market cap stands at $1.4 billion. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Babcock &amp; Wilcox Enterprises, Inc. 6.50% Senior Notes due 2026 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWNB#NYSE">BWNB</a>) shares moved upwards by 21.76% to $9.57. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vast Renewables (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTE#NASDAQ">VSTE</a>) stock declined by 58.0% to $0.15 during Wednesday's regular session. The company's market cap stands at $4.6 million. </li>
<li>Vestis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSTS#NYSE">VSTS</a>) stock fell 37.61% to $5.43. The market value of their outstanding shares is at $716.0 million. As per the news, the Q2 earnings report came out yesterday. </li>
<li>Costamare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMRE#NYSE">CMRE</a>) stock decreased by 23.6% to $7.04. The market value of their outstanding shares is at $845.1 million. </li>
<li>New Century Logistics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCEW#NASDAQ">NCEW</a>) stock decreased by 21.98% to $1.74. The company's market cap stands at $37.4 million. </li>
<li>MasterBrand (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MBC#NYSE">MBC</a>) shares declined by 14.45% to $10.25. The company's market cap stands at $1.3 billion. As per the news, the Q1 earnings report came out yesterday. </li>
<li>ConnectM Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTM#NASDAQ">CNTM</a>) stock fell 14.33% to $0.56. The company's market cap stands at $16.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BWNB

CIGL

CMRE

CNTM

EOSE

GPUS

Citigroup Financial 300% Minupon Princ Protected Nts for Russell 2000 Index

NCEW

ONEG

VSTE

VSTS

12 Industrials Stocks Moving In Wednesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Porch Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCH#NASDAQ">PRCH</a>) stock rose 58.4% to $10.04 during Wednesday's regular session. The market value of their outstanding shares is at $1.0 billion. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Gen Digital Inc. - Contingent Value Rights (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GENVR#NASDAQ">GENVR</a>) stock rose 30.74% to $6.63. </li>
<li>Kimball Electronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KE#NASDAQ">KE</a>) shares moved upwards by 21.04% to $17.81. The market value of their outstanding shares is at $439.4 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Nortech Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSYS#NASDAQ">NSYS</a>) stock increased by 20.15% to $11.04. The company's market cap stands at $30.4 million. </li>
<li>Atomera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATOM#NASDAQ">ATOM</a>) stock rose 15.32% to $5.85. The market value of their outstanding shares is at $179.5 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Digital Turbine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPS#NASDAQ">APPS</a>) stock moved upwards by 15.24% to $3.56. The company's market cap stands at $373.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>FOXO Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/FOXO#AMEX">FOXO</a>) shares decreased by 50.7% to $0.79 during Wednesday's regular session. The company's market cap stands at $2.8 million. </li>
<li>MicroAlgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NASDAQ">MLGO</a>) stock decreased by 24.72% to $2.65. The company's market cap stands at $26.4 million. </li>
<li>CPI Card (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMTS#NASDAQ">PMTS</a>) stock fell 20.66% to $20.11. The market value of their outstanding shares is at $226.8 million. As per the press release, Q1 earnings came out today. </li>
<li>CEVA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEVA#NASDAQ">CEVA</a>) stock decreased by 19.6% to $21.29. The company's market cap stands at $509.0 million. The company's, Q1 earnings came out today. </li>
<li>Synchronoss Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNCR#NASDAQ">SNCR</a>) shares decreased by 17.26% to $8.54. The company's market cap stands at $98.1 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Diginex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGNX#NASDAQ">DGNX</a>) shares fell 17.24% to $63.0. The company's market cap stands at $1.4 billion. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APPS

ATOM

CEVA

DGNX

FOXO

GENVR

MLGO

NSYS

PMTS

PRCH

SNCR

12 Information Technology Stocks Moving In Wednesday's Intraday Session

RBC Capital analyst Brad Erickson reiterates DoorDash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) with a Outperform and maintains $230 price target.

Reiteration

DASH

RBC Capital Reiterates Outperform on DoorDash, Maintains $230 Price Target

Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) shares are trading higher Wednesday after the company reported better-than-expected first-quarter financial results on Monday after <a href="https://www.benzinga.com//node/45237261">the market closed.</a>
What To Know: The company reported adjusted earnings per share of 96 cents, beating the consensus estimate of 94 cents. In addition, AMD reported sales of $7.44 billion, beating the consensus estimate of $7.13 billion and representing a 36% year-over-year growth.
The company provided a segment breakdown, reporting $3.7 billion in Data Center revenue, $2.9 billion from its Client and Gaming segment and $823 million from its Embedded segment. Data Center revenue rose 57% year-over-year, while Client and Gaming revenue climbed 68%.
&#8220;We delivered an outstanding start to 2025 as year-over-year growth accelerated for the fourth consecutive quarter driven by strength in our core businesses and expanding data center and AI momentum,&#8221; said Dr. Lisa Su, AMD chair and CEO. 
&#8220;Despite the dynamic macro and regulatory environment, our&nbsp;first quarter&nbsp;results and&nbsp;second quarter&nbsp;outlook&nbsp;highlight the strength of our differentiated product portfolio and consistent execution positioning us well for strong growth in 2025.&#8221;
Outlook: The company sees second-quarter sales from $7.10 billion to $7.70 billion, versus the consensus estimate of $7.24 billion.
Analyst Changes: Following the earnings report, multiple analysts issued price target adjustments.
<ul>
<li>Raymond James analyst Srini Pajjuri reiterated an Outperform rating on AMD and lowered the price target from&nbsp;$150&nbsp;to&nbsp;$120.</li>
<li>UBS analyst Timothy Arcuri maintained a Buy rating on AMD and lowered the price target from&nbsp;$155&nbsp;to&nbsp;$150.</li>
<li>Piper Sandler analyst Harsh Kumar reiterated an Overweight rating on AMD and lowered the price target from&nbsp;$140&nbsp;to&nbsp;$125.</li>
<li>Loop Capital analyst Gary Mobley maintained a Buy rating on AMD and lowered the price target from&nbsp;$175&nbsp;to&nbsp;$140.</li>
</ul>
See Also: <a href="https://www.benzinga.com/25/05/45259638/celanese-analysts-boost-their-forecasts-after-upbeat-q1-results">Celanese Analysts Boost Their Forecasts After Upbeat Q1 Results</a>
AMD Price Action: At the time of writing, AMD stock is trading 0.65% higher at $99.22, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro.</a>
Image: Courtesy of Advanced Micro Devices, Inc.

What's Going On With Advanced Micro Devices Stock Wednesday?

Ready Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RC#NYSE">RC</a>) is preparing to release its quarterly earnings on Thursday, 2025-05-08. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Ready Capital to report an earnings per share (EPS) of $0.27.
Ready Capital bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Overview of Past Earnings</h3>
Last quarter the company missed EPS by $0.24, which was followed by a 2.37% drop in the share price the next day.

<img src="https://www.benzinga.com/files/images/story/2025/1746637479_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Ready Capital were trading at $4.36 as of May 06. Over the last 52-week period, shares are down 48.67%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/RC/earnings">To track all earnings releases for Ready Capital visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

An Overview of Ready Capital's Earnings

RBC Capital analyst Matthew Hedberg maintains Datadog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) with a Outperform and maintains $119 price target.

DDOG

RBC Capital Maintains Outperform on Datadog, Maintains $119 Price Target

Press Releases

MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site

MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End

MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development

MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain

MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain

MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development

MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain

MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion

MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation

MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity

MIRA

Aspire Biopharma Holdings, Inc. - Common Stock

Aspire Biopharma Hldgs

Athira Pharma

CalciMedica

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Cingulate

Cocrystal Pharma

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Dare Bioscience

Durect

Gelteq

Hoth Therapeutics

IGC Pharma

Iterum Therapeutics

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

Lexaria Bioscience

Lipocine

NRX Pharmaceuticals

Pulmatrix

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics

Scilex Holding

China SXT Pharmaceuticals, Inc. - Common Stock

China SXT Pharmaceuticals

Talphera

TherapeuticsMD

VYNE Therapeutics

Rodman & Renshaw

Ascendiant Capital

Screenshot 2024-10-02 at 5.44.40 PM

Breakthrough Therapies And Novel Treatments - This Biopharma Is Out To Change The Game

Screenshot 2024-09-18 at 6.27.57 PM

MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing On Early Clinical Efficacy Demonstration For Neuropathic Pain In 2025

Screenshot 2024-09-04 at 6.19.41 PM

TELO

Telomir Pharmaceuticals (NASDAQ: TELO) Featured In Local ABC Exclusive Showing Positive Outcomes Of Proposed Age Reversal Pill In Dogs

Screenshot 2024-08-26 at 4.53.37 PM

The Potential Of Ketamir-2: A Safer Treatment For Mental Health Disorders And Neuropathic Pain, IND Filing Expected By Year-End

Screenshot 2024-07-25 at 6.08.16 PM

MIRA Pharmaceuticals (NASDAQ: MIRA) Reports Promising Pre-Clinical Trial Results For Mental Health Treatment, To Submit Investigational New Drug Application By End Of Year

Comments

Mira Pharmaceuticals

Mira Pharmaceuticals (MIRA) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル